Mitsuo Fujinami
Private Equity Investor at BioFrontier Partners, Inc.
Network origin in Mitsuo Fujinami first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
BioFrontier Partners, Inc.
 BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan.
2
| Private Company | Investment Managers | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mitsuo Fujinami via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HUMAN METABOLOME TECHNOLOGIES, INC. | Biotechnology | Founder | |
| Tohoku University | College/University | Doctorate Degree | |
GeneCare Research Institute Co., Ltd.
 GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Medical/Nursing Services | Director/Board Member | |
Healthcare Innovation Co. Ltd.
 Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Investment Managers | Chairman | |
Cell-Medicine, Inc.
 Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Pharmaceuticals: Major | Director/Board Member | |
| Texas A&M University | College/University | Graduate Degree |
Statistics
International
| Japan | 6 |
| United States | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
| Finance | 2 |
Operational
| Chairman | 2 |
| Director/Board Member | 2 |
| President | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Yoshihiro Otaki | 6 |
| Hinako Schroeter | 2 |
- Stock Market
- Insiders
- Mitsuo Fujinami
- Company connections
